Autopsy report · NCT03422874

Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma

“Sponsor withdrew support”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Dartmouth-Hitchcock Medical Center

Sponsor type

University, hospital or other

Conditions

Neoplasms; Lymphoma

Interventions

MLN9708; Nelfinavir

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Study of Regional Cerebral Oxygenation and Brain Blood Volume Changes During Carotid Endarterectomy Using the NeurOS System
  “sponsor withdrew” (93% match in meaning)
• BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
  “Withdrawal of sponsor support” (93% match in meaning)
• An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.
  “Sponsor withdrawn” (91% match in meaning)
• Ultrasound Image Fusion for Placement of Sacral Quadripolar Leads
  “Sponsor withdrew funding” (89% match in meaning)
• BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
  “Withdrawn by sponsor” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.